TriangleRibociclib (NCT05467891)
Ribociclib trial for Locoregional Recurrence (NCT05467891). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with locally or regionally recurrent hormone-receptor-positive, HER2-negative breast cancer after adequate local treatment. Distant metastases are excluded.
The idea: ribociclib blocks CDK4/6 proteins that drive cell division. Patients take 400 milligrams daily for twenty-one days per twenty-eight-day cycle, for three years. Their doctor selects fulvestrant, anastrozole, letrozole, or exemestane for five years. Premenopausal patients need ovarian suppression or prior ovary removal. Researchers measure recurrence and safety.
This phase 2 study plans 200 patients. Oana Danciu leads at the University of Illinois Chicago; nineteen US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.